drugset / Trial / NCT04572243
A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary purpose of the study is to demonstrate that lorcaserin has superior efficacy compared to placebo on percent change in frequency of convulsive seizures per 28 days in participants with Dravet syndrome.
Timeline
- Start
- 2020-09-23
- Primary completion
- 2024-08-15
- Completion
- 2024-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lorcaserin | Small molecule | 5 mg | Oral |
| Subject | Lorcaserin | Small molecule | 10 mg | Oral |
| Subject | Lorcaserin | Small molecule | 20 mg | Oral |